Trial reportInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2026
Comparison of the immunogenicity of adjuvanted and conventional egg-based quadrivalent influenza vaccines among healthcare personnel in Lima, Peru: A randomized controlled trial.
Trial report in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06054269 (Randomized Controlled Trial, Double Blind, Phase III, to Evaluate the Immunogenicity of an Adjuvanted Influenza Vaccine Among Health Care Personnel), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized Controlled Trial, Double Blind, Phase III, to Evaluate the Immunogenicity of an Adjuvanted Influenza Vaccine Among Health Care Personnel (EDUCATE)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
objectivesWe conducted a randomized controlled trial to evaluate whether adjuvanted quadrivalent inactivated influenza vaccine (aIIV4) generates superior immunogenicity against influenza viruses compared to conventional quadrivalent inactivated influenza vaccine (IIV4) among healthcare personnel (HCP) in Lima, Peru.
methodsDuring 2022-2023, we randomized 192 HCP aged ≥18 years to receive 2022 Southern Hemisphere IIV4 or aIIV4 and collected pre-, 1-month post-, and 6-months post-vaccination sera. Geometric mean titers (GMTs), GMT ratios, seroconversion rates (SCR), and seroprotection rates (SPR) were compared against vaccine reference viruses-influenza A(H1N1)pdm09, A(H3N2), B/Victoria, and B/Yamagata-using hemagglutination inhibition assays.
resultsMost HCP (77-99%) had titers ≥40 following vaccination. One-month post-vaccination, aIIV4 induced higher GMTs (GMT ratio: 1.7 [95% confidence interval 1.1-2.7]) and SCR (88.4% [80.4-93.4] vs 62.1% [52.1-71.2]) against A(H1N1)pdm09 and higher SCR (82.1% [73.2-88.5] vs 62.1% [52.1-71.2]) against A(H3N2) compared to IIV4. At 6 months, aIIV4 induced higher SPR against A(H3N2) (90.4% [82.8-94.9] vs 74.0% [64.4-81.7]) than IIV4. IIV4 recipients vaccinated the preceding influenza season had lower odds of seroconverting to A(H1N1)pdm09 compared to IIV4 recipients who were not vaccinated (adjusted odds ratio: 0.29 [0.13-0.63], P = 0.002).
conclusionThese findings provide insights into the benefits of an enhanced influenza vaccine (aIIV4) to help overcome the immune blunting effects of repeat vaccination among HCP. CLINICAL TRIALS REGISTRATION: NCT06054269.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.